Chemolab Therapeutics and Scipher Medicine announced plans to merge and rebrand as Scipher Medicine Corporation, positioning the combined company to advance nebokitug toward a phase 2 trial in rheumatoid arthritis. The merger sets a 68%/32% split between existing Scipher and Chemomab (Chemolab) equity holders and keeps Scipher CEO Reginald Seeto at the helm. Management said the initial focus will be on nebokitug, an anti-CCL24 monoclonal antibody, after preclinical work suggested potential across immune-fibrotic disorders. A topline readout is expected in the first half of 2028, and the phase 2 trial is planned using standard FDA RA endpoints and PrismRA to guide enrollment. Scipher also highlighted its blood-based PrismRA assay, plus an AI Network Medicine platform that prioritized CCL24 and developed a proprietary response signature. The transaction is supported by approximately $30 million in commitments from current investors, with closing cash projected to fund operations through mid-to-late 2028.